Press Release

BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New Jersey AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of…

Management to Announce Earnings Results and hold a call at 8:30 am ET AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial…

Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipeline AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued…

Dear Shareholder, Yesterday, it was my honor to share news of an exciting development that we believe will shape Aspira Women’s Health for many years to come. We have been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health, an initiative to address critical unmet…

SUMMARY: The addition of miRNA and metadata to Aspira’s existing protein assay shows promising improvements in both sensitivity and specificity for early-stage ovarian cancer in women with an adnexal mass AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development…

AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11,…

SUMMARY: The innovative new tool will be made available for integration into Electronic Medical Records at over 300 clinical sites serving 2,500 clinical users AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today…

SUMMARY Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc.…

Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner’s in Women’s Health (NPWH) Woman’s Healthcare…